Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Overview

This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).

Full Title of Study: “A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 1, 2027

Detailed Description

The study will be conducted in two phases: – Phase 1: Dose escalation in R/R MM – Phase 2: Dose expansions in select R/R MM – Cohort A: R/R MM – Cohort B: R/R MM Post-T-Cell Directed Therapy Participants will be treated at escalating dose levels in Phase 1 (dose-escalation phase) of the study. Once the safety of ISB 1442 is confirmed and a Recommended Phase 2 Dose (RP2D) is established in Phase 1 for a given indication, Phase 2 will be initiated for that indication. Participants will receive ISB 1442, until disease progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.

Interventions

  • Drug: ISB 1442 SC injection escalating doses
    • Participants will receive escalating SC doses of ISB 1442
  • Drug: ISB 1442 SC injection at RP2D
    • ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met

Arms, Groups and Cohorts

  • Experimental: Phase 1: Dose escalation
    • Participants with R/R multiple myeloma (MM) will be administered ISB 1442 weekly by subcutaneous (SC) injection in each 28-day cycle. Dose escalation will begin with an accelerated titration dose escalation and should certain conversion criteria be met, escalation will convert to the standard (3 + 3) dose escalation
  • Experimental: Phase 2 (Dose Expansion): Cohort A: R/R Multiple Myeloma
    • This cohort includes the participants with pathologically confirmed R/R MM and must have received at least 3 prior lines of therapy, including proteasome inhibitors (PIs), immunomodulators (IMiDs), and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. Participants will receive the recommended Phase 2 Dose (RP2D) of ISB 1442 SC injection determined in Phase 1 of the study for treatment of R/R MM. Each treatment cycle duration is 28 days. The anticipated total duration for each participant will vary, depending on the number of cycles of treatment completed. The treatment phase will extend until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met.
  • Experimental: Phase 2 (Dose Expansion): Cohort B: R/R MM Post-T-cell-Directed Therapy
    • This cohort includes the participants with pathologically confirmed R/R MM post T cell-directed therapy and have received prior treatment with proteasome inhibitors (PIs), immunomodulators (IMiDs), and anti-CD38 therapies either in combination or as a single agent; and must have failed at least 3 prior lines of treatment. Participants will receive the RP2D of ISB 1442 SC injection determined in Phase 1 of the study. Each treatment cycle duration is 28 days. The anticipated total duration for each participant will vary, depending on the number of cycles of treatment completed. The treatment phase will extend until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met.

Clinical Trial Outcome Measures

Primary Measures

  • Phase 1: Frequency and Severity Of Treatment-Emergent Adverse Events (TEAEs)
    • Time Frame: Up to 18 months
  • Phase 1: Number of Dose-Limiting Toxicities (DLTS) During the First 28 Days After the First Administration of ISB 1442 (Cycle 1)
    • Time Frame: Up to 28 days
  • Phase 2: Multiple Myeloma: Overall Response Rate (ORR) Based on International Myeloma Working Group (IMWG)
    • Time Frame: 18 months

Secondary Measures

  • Maximum Concentration (Cmax) of ISB 1442 in Serum
    • Time Frame: Up to 28 days
  • Time to Reach Maximum Concentration (Tmax) of ISB 1442 in Serum
    • Time Frame: Up to 28 days
  • Area Under the Concentration Time Curve From Zero to Time t (AUC0-t) of ISB 1442 in Serum
    • Time Frame: Up to 28 days
  • Area Under the Concentration Time Curve in Dosing Intervals (AUC0-tau) of ISB1442 in Serum
    • Time Frame: Up to 28 days
  • Percent Incidence of Anti-Drug Antibody (ADA) and Neutralizing Antibody (nAb) From Baseline Until End-of-Treatment (EOT)
    • Time Frame: Baseline to 18 months
  • Phase 1 and Phase 2: Time to Progression (TTP)
    • Time Frame: 18 Months
  • Phase 1 and Phase 2: Time to Next Treatment (TTNT)
    • Time Frame: 18 Months
  • Phase 1 and Phase 2: Time to Response (TTR)
    • Time Frame: 18 Months
  • Phase 1 and Phase 2: Progression free survival (PFS)
    • Time Frame: 18 Months
  • Phase 1 and Phase 2: Overall survival (OS)
    • Time Frame: 18 Months
  • Phase 1: Overall Response Rate (ORR) Based on International Myeloma Working Group (IMWG)
    • Time Frame: 18 months
  • Phase 1 and Phase 2: Complete Response Rate (CRR) Based on International Myeloma Working Group (IMWG)
    • Time Frame: 18 months
  • Phase 1 and Phase 2: Duration of Response (DOR) Based on International Myeloma Working Group (IMWG)
    • Time Frame: 18 months
  • Phase 2: Frequency and Severity of Treatment Emergent Adverse Events (TEAEs)
    • Time Frame: 18 months

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female patients aged 18 years or older. 2. Be willing and able to provide written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act of 1996 [HIPAA]) prior to any protocol related procedures, including screening evaluations 3. Phase 1: Patients with pathologically confirmed multiple myeloma (MM) who have progressed on or after standard therapy (relapsed/refractory [R/R] patients): 1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. (Note: Patients in Australia may have received any of the therapies including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit ). 2. Must have measurable M-protein (serum and/or 24-hr urine, or serum free light chains). 4. Phase 2: Patients with pathologically confirmed MM who have progressed on or after standard therapy (R/R patients): Cohort A: R/R MM 1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; 2. Must have measurable disease defined by at least 1 of the following abnormalities (as per IMWG criteria):

  • Serum M-protein ≥ 0.5 g/L (IgA ≥ 0.5 g/L), or – Urine light-chain (M-protein) of ≥ 200 mg/24 hours, or – Serum free light chain (sFLC) assay: involved free light chain (FLC) level ≥ 10 mg/dL provided sFLC ratio is abnormal. Cohort B: R/R MM Post-T-Cell Directed Therapy 1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs and anti-CD38 therapies either in combination or as a single agent; and have relapsed and/or be refractory to a T-cell directed therapy including cellular therapies or T cell engagers. 2. Must have measurable disease defined by at least 1 of the following abnormalities (as per IMWG criteria): – Serum M-protein ≥ 0.5 g/L (IgA ≥ 0.5 g/L), or – Urine light-chain (M-protein) of ≥ 200 mg/24 hours, or – sFLC assay: involved FLC level ≥ 10 mg/dL provided sFLC ratio is abnormal 5. Have a body weight ≥ 40.0 kg at screening. 6. Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less. 7. Have life expectancy of at least 3 months (from date of informed consent signing). 8. Have adequate organ function, including: 1. Aspartate aminotransferase (AST, GOT) and alanine aminotransferase (ALT, GPT) ≤3.0 × ULN; bilirubin ≤1.5 × ULN. Patients with Gilbert's syndrome may have a bilirubin level >1.5 × ULN, per discussion between the Investigator and medical monitor. 2. Estimated creatinine clearance ≥45 mL/min as calculated using the Cockcroft-Gault formula or 24-hour urine collection. 9. Left ventricular ejection fraction (LVEF) ≥45% as assessed by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan. Exclusion Criteria:

1. Participants with relapsed disease where relapse is characterized only by minimal residual disease parameters (i.e., minimal residual disease positive). 2. Participants with MM with disease where the only measurable parameter is plasmacytoma. 3. Received treatment with anti-CD38 antibodies or CD47 targeted therapies within 1 month of C1D1; systemic anticancer treatments within 14 days before the first dose of study drug (C1D1) or any investigational products within 5 half-lives of C1D1, whichever is appropriate to last therapy received. (eg, non-IMP IMiD, proteasome inhibitor could be considered to be eligible if there is at least 14 days after last dose before C1D1. Note: Treatment with a single course of glucocorticoids is allowed (maximum dose of corticosteroids should not exceed the equivalent of 160 mg [for example, 40 mg/d for 4 days] of dexamethasone). Hormonal therapy for prostate cancer or breast cancer (as adjuvant treatment), and treatment with bisphosphonates and receptor activator of nuclear factor kappa-Β ligand inhibitors are allowed. 4. Received autologous stem cell transplantation within 12 weeks of C1D1. 5. Current participation in another interventional study, including other clinical trials with investigational agents (including investigational vaccines or investigational medical device for disease under study) within 4 weeks of C1D1 and throughout the duration of this trial. 6. Prior radiation therapy within 14 days of C1D1; or prior irradiation to > 25% of the bone marrow. Note: Prophylactic localized ("spot") radiation for areas of pain is allowed. 7. Active malignant central nervous system involvement 8. Known to be refractory to platelet or RBC transfusions 9. Known severe allergic or anaphylactic reactions to human recombinant proteins or excipients used in the ISB 1442 formulation. 10. QTc interval > 480 msec at screening using Fredericia's QT correction formula.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ichnos Sciences SA
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Ichnos Sciencesrator Clinical Trials Administrator, (315) 583-1249, clinicaltrials@ichnossciences.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.